Effect of Chronic Commercial Sweeteners Consumption in Lymphocytes of Peyer’s Patches

Julio Andrés Guzmán-Cruz¹, Beatríz Elina Martínez-Carrillo¹*, Arturo G. Rillo¹, José Arturo Castillo-Cardiel² and Flor de María Cruz-Estrada¹

¹Laboratorio de Investigación en Nutrición, Facultad de Medicina, Universidad Autónoma del Estado de México, México.
²Departamento de Cirugía experimental, Universidad Quetzalcóatl, Irapuato, Guanajuato, México.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors JAGC and BEMC designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors BEMC, AGR and JACC managed the analyses of the study. Author FMCE managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/EJNFS/2019/v9i430082

Received 12 May 2019
Accepted 22 July 2019
Published 30 July 2019

ABSTRACT

Aims: To know the effect of chronic commercial sweeteners consumption in lymphocytes of Peyer’s patches.
Study Design: A prospective, longitudinal, comparative and experimental study.
Place and Duration of Study: The study was conducted in the Nutrition Research Laboratory of the Faculty of Medicine of Universidad Autónoma del Estado de México (UAEMéx) between August 2018 and May 2019 and was approved by the Bioethics Committee.
Materials and Methods: Two groups of male mice of different strains were used: 1) Balb/c and 2) CD1, both at 8-weeks-old age. The groups were divided into 4 subgroups: 1) Control (without sweetener), 2) Sucrose (table sugar, 41.66 mg/mL), and two groups of commercial sweeteners 3) Splenda® (sucralose 1.2%, with a concentration of 4.16 mg/mL), and 4) Svetia® (Steviol glycoside 0.025 g with a concentration of 4.16 mg/mL). The mice consumed the supplementation for 6 weeks. Also, were quantified plasma glucose, percentage of lymphocytes from Peyer’s patches, water and food consumption weekly.

*Corresponding author: Email: martinez_elina9@hotmail.com, marbety9@gmail.com;
Results: Mice increased their body weight after 6 weeks of treatment. The animals of Control and Sucrose subgroups showed a significant body weight gain of 5 g compared with the Splenda® and Svetia® subgroups, which increased only 4 g. In the subgroup treated with Splenda®, the blood glucose was reduced significantly. Svetia® and Control groups consumed more water without sweetener. The differences in food consumption were between the subgroups, not between the strains. By the end, the percentage of lymphocytes from Peyer’s patches increased in the Sucrose subgroup but decreased significantly in other subgroups.

Conclusion: The consumption of sweeteners may modify the lymphocyte population of Peyer’s patches in the small intestine and this variation depends on the frequency of consumption the strain of the rodents and the type of sweetener.

Keywords: Sweeteners; Peyer’s patches; lymphocytes; body weight; blood glucose; water consumption.

1. INTRODUCTION

Sweeteners are chemical compounds that can produce a sensation of sweetness [1] and they have various effects on health [2,3]. Sucrose (table sugar), is the oldest used sweetener and provides energy to the body [4]. The increase in chronic non-communicable diseases and sedentary lifestyle are causing consumers to look for products that are reduced in energy and therefore in sugar, using more and more non-caloric commercial substitutes [5]. These offer a sweet taste to food, but with a lower energy content [6,7]. The preference for sweet taste varies according to genetics and age [8], it is fundamental in the nutritional status [9], therefore, there is a need to look for sugar substitutes, with a similar effect on taste, but with less energy [10]. Sweeteners are classified as natural and artificial [11]. Artificial as sucralose, are produced by chemical synthesis, have little or no energy supply, with power than sucrose sweetener [12]. This sweetener was synthesized in 1976 and is approximately 600 times sweeter than sucrose [13]. It is manufactured by selective halogenation of sucrose, is thermostable, resists a wide variety of pH, is not metabolized or stored in the body, and is excreted unchanged in urine and faeces [14]. 85% of sucralose is not absorbed, the remaining 15% is absorbed by passive diffusion [15]. Baird, IM et al, in 2000, published a study related to the tolerance of sucralose in humans, they confirm that it does not generate adverse effects on health [16]. Among the natural we found stevia, it’s come from vegetable products, give energy power and they have a sweetening power inferior or similar to sucrose (300 times sweeter than sucrose) [17, 18]. Steviol glycosides isolated from the leaves of the plant, Stevia Rebaudiana Bertoni, contains a Stevioside and Rebaudioside A [19]. Their metabolism begins in the intestine, they are broken down to steviol with help of the intestinal microbiota, mainly by Bacteroides sp., and they are absorbed by facilitated diffusion to the blood. Finally, steviol is secreted in the urine as steviol glucuronide and in faeces like free steviol [20,21]. Stevia is safe when used as a sweetener, suitable for diabetic patients, with phenylketonuria, obese and for those who wish to avoid the consumption of sugar in the diet [22]. It is known that its use does not alter blood glucose concentrations [23], for which they are well accepted in diabetic patients [24], do not contribute to dental caries [25] and can be used in pregnant women [26].

The gut-associated with lymphoid tissue (GALT) is located in the mucosa of the gastrointestinal tract [27], contains the largest surface area of exposure to microorganisms, as it contains a diverse and dense microbiota that are not pathogenic to the host [28,29]. The mucosa of the gastrointestinal tract can identify pathogenic and nonpathogenic substances, and therefore discern between producing or not, an immune response [30]. The immunological defense in the intestine is carried out by the GALT lymphocytes, organized in compartments, the Peyer’s patches (inductor site), the lamina propria (effector site) and the isolated lymphoid follicles (ILF) [31]. The most important of these structures is that they contain a large number of cells, derived from a cellular precursor generated in the bone marrow [32]. In the small intestine, there are about 200 Peyer’s patches (PP), each one consists in aggregates of B cells (lymphoid follicles), surrounded by rich areas in T cells and antigen-presenting cells (APCs) [33]. On its surface, there are flattened epithelial cells with few villi and mucus-producing cells [34]. The PP can be considered as the immunological sensors of the intestine and are an initial contact site with the antigens [35]. When antigenic stimulation occurs...
in the PP, the lymphocytes migrate to the blood, proliferate and differentiate in the spleen before returning to the lamina propria and other areas of the mucosa [31].

The effect of sweeteners on the immune system is controversial and is not yet clear. It has been observed that the use of glucose, fructose and sucrose, cause reduction of phagocytic activity of peripheral blood neutrophils [36]. The effect of sucralose has been studied in lymphoid organs such as spleen and thymus [37], doses greater than 3000 mg/kg showed changes in the thymus [38] and reductions in peripheral white blood cells and lymphocyte count have been observed [39]. On the other hand, stevia administered at different doses increased phagocytic activity and proliferation of T cells [40]. In another study, they found that steviol has not any effect on the release of TNF-α, and IL-1β in THP-1 human monocyctic cells when stimulated by LPS [41]. In human colon carcinoma cell lines, the effect of stevioside on the release of IL-8 was studied, using TNF-α as a stimulator, they found that steviol reduces the expression of NF-kB [42].

Intending to improve the quality of food, sugars are partially or replaced by sweeteners, this is seen in the increase of commercial products that contain them [43]. Splenda® contains sucralose (1.2%) and Svetia® has steviol glycoside (0.025 g), both are the most used commercial forms in Mexico, are distributed in restaurants and are sold in all markets and malls.

These sweeteners are used as additives in more than 50% of low-calorie commercial products [44] and taking into account that Peyer's patches are the first immunological contact zone of sweeteners in the GI system, it is necessary to know the effect of chronic commercial sweeteners consumption in lymphocytes of Peyer's patches.

2. MATERIALS AND METHODS

2.1 Study Design

A prospective, longitudinal, comparative and experimental study was carried out. Two different strains of mice (male) were used: Balb/c and CD1, these strains of mice were selected, as they have been used as models to test diets with different proportions of lipids, carbohydrates and some micronutrients. Also, because they are not obese strains such as db/db and ob/ob mice. This allows us to evaluate the effect of diets and different nutrients in a healthy animal model [45,46,47,48]. The objective of using this strain was to work with healthy rodent models, to know the effect of sweeteners on healthy subjects before the disease is established.

Were used 64 Balb/c and CD1 male mice, from 8 weeks old, weighing between 19.5 g and 22.3 g. Both groups were fed normal standard food Rodent Laboratory Chow 5001 from Purina and water ad libitum. They were kept in plastic cages in groups of 4 each, under pathogen-free conditions and with light/dark cycles of 12 hours. The study was conducted in the Nutrition Research Laboratory of the Faculty of Medicine of the Universidad Autónoma del Estado de México (UAEM) and was approved by the Bioethics Committee of the same faculty. The mice were managed based on NOM-062-ZOO-1999, Specifications for the production, care and use of laboratory animals [49].

2.2 Distribution of Groups and Administration of Sweeteners

The mice were distributed into two groups: Group 1) Balb/c strain mice and Group 2) CD1 strain mice. Each group were divided into 4 subgroups (n=8): A) Control Group (CL), without sweetener, B) Sucrose Group (Suc), C) Splenda® Group (Spl), D) Svetia® Group (Svt).

The trademarks of Splenda® and Svetia® were used, which are the most used by the Mexican population. One envelope of Splenda® contains 1 g of carbohydrates, which includes: dextrin (95.8%), maltodextrin (3%) and sucralose (1.2%, equivalent to 12 mg of sucralose). One envelope of Svetia® contains 1 g of carbohydrates which includes: sucrose, steviol glycoside (0.025 g), isomalt and sucralose (0.006 g). The solutions were prepared with the treatments (sweeteners) in ultrapure water obtained by Milli-Q® IQ System 7003/05/10/15, they were placed in the drinkers daily, for oral consumption during the 24 h the 7 days of the week. The concentration used was 41.66 mg/mL of Sucrose (Table sugar) and 4.16 mg / mL of Splenda® and Svetia® by the recommendations of Official Mexican Standard NOM-218-SSA1-2011 for non-alcoholic flavored drinks [50]. The treatment was administered for 6 weeks, starting on the 60th day old of the animals.

2.3 Determination of Body Weight and Blood Glucose

Quantification of body weight was performed weekly, starting at week 8. Weight
measurements were made with anaesthetized mice (0.1 mL of 1% sodium pentobarbital).

The concentration of peripheral blood glucose was quantified weekly with an Accu-Chek Perform glucometer (© 2019 Roche DC México, Cat. No. 2326E2014 SSA). The sample was collected from the middle third of the tail.

2.4 Water Consumption Quantification

The water consumption was done by placing 250 mL of water with or without sweetener in each drinker, at 24 h the volume of water consumed was measured and subtracted from the water that remained in the drinking fountain.

2.5 Obtaining Samples

After 6 weeks of treatment, the animals were anaesthetized with 0.1 mL of 1% sodium pentobarbital and sacrificed by cervical dislocation. One millilitre of blood was obtained by direct cardiac puncture (using a syringe with 50 μl of heparin); from the millilitre of blood, the lymphocytes were purified by density gradient with Lymphoprep™ (Axis-Shield) [51]. The small intestine was removed, and Peyer's patches were removed from it.

Once the Peyer's patches were removed, they were placed in Petri dishes with RPMI medium (3 mL), manually homogenized and filtered with nylon mesh (40-μm) to eliminate the remaining connective tissue. Centrifuged at 2500 rpm / 5 min, the cell button obtained from the Peyer's patches were placed in a hypotonic buffer solution (8.26 g/L of NH₄Cl, 1 g/L of KHCO₃ and 0.037 g/L of EDTA-4Na, with a pH of 7.4) to lyse the erythrocytes. The cell suspension isolated from the Peyer's patches was washed with PBS. The cell viability of the isolated lymphocytes was immediately evaluated with a trypan blue assay. The lymphocytes were counted with the Neubauer chamber to obtain the cellular percentage per mL of cell suspension.

2.6 Statistical Analysis

The statistical package SPSS version 19 for Windows was used to analyze the data. Tests were made of central tendency (mean), dispersion (standard deviation) and means were compared employing one-way analysis of variance ANOVA, with Tukey's post hoc test to evaluate intra-group differences. Significance was considered with p<0.05.

3. RESULTS

3.1 Changes in Body Weight after Consumption of Sweeteners

All mice in group 1 significantly increased their body weight after 6 weeks of treatment. The animals of Control and Sucrose subgroups showed a significant gain of 5 g of weight (p<0.001), compared with the Splenda® and Svetia® subgroups, which increased 4 g (Table 1). In group 2 the increase in weight was similar, the mice of the Control and Sucrose subgroups increased on average 4 g of weight and the subgroups of Splenda® and Svetia® only 3 g (p<0.014). Svetia's® group had the lowest weight gain (3 g), compared to Control (p<0.009), as shown in Table 1. When comparing group 1 with group 2, significant differences were found (p<0.001), the weight of animals of group 1 was lower than those of group 2, although the behavior of weight gain was similar.

Table 1. The average weight of mice after 6 weeks of supplementation with sweeteners

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Sucrose</th>
<th>Splenda®</th>
<th>Svetia®</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ±SD (g)</td>
<td>Mean ±SD (g)</td>
<td>Mean ±SD (g)</td>
<td>Mean ±SD (g)</td>
<td></td>
</tr>
<tr>
<td>Body weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before intervention</td>
<td>23.1±0.95</td>
<td>23.9±1.0</td>
<td>20.8±0.58</td>
<td>20.5±1.4</td>
<td>0.001*</td>
</tr>
<tr>
<td></td>
<td>40.5±0.59</td>
<td>37.8±1.1</td>
<td>40.1±3.49</td>
<td>37.5±1.8</td>
<td>0.009*</td>
</tr>
<tr>
<td>After intervention (6 weeks)</td>
<td>28.3±1.05</td>
<td>28.8±1.2</td>
<td>24.5±0.6</td>
<td>24.9±1.2</td>
<td>0.001*</td>
</tr>
<tr>
<td></td>
<td>44.4±0.44</td>
<td>41.4±1.5</td>
<td>43.6±4.2</td>
<td>40.6±2</td>
<td>0.014*</td>
</tr>
</tbody>
</table>

One-way ANOVA was performed to determine the differences between the subgroups, it was considered significant with p<0.05. A Bonferroni post hoc test* was performed to observe intra-group differences
3.2 Glycaemia

The glucose in group 1 showed no significant differences (p<0.122) between the subgroups. In group 2, the blood glucose concentration was higher, the subgroup of Splenda® significantly reduced blood glucose (p<0.001), compared with the Control, Sucrose and Svetia® subgroups. When comparing the groups, differences were found between them (p<0.001), group 1 had lower glucose concentrations, even in the control groups (Table 2).

3.3 Water with and without Sweetener

Group 1 consumed more water with Sucrose and little water with Splenda® (p<0.001), compared with the Svetia® and Control groups that consumed more water without sweetener (Table 3). In contrast, group 2 consumed more water with Svetia® after the intervention, without differences between water consumption with Sucrose, Splenda® and Control group, as shown in Table 3. When comparing the groups, it can be seen that group 1 consumed more water with Sucrose than group 2, in both periods before and after interventions (p<0.004), as shown in Table 3.

3.4 Food Consumption

The subgroups of Sucrose and Splenda® consumed less food (p<0.001), compared to the Control and Svetia® subgroups. At the end of the 6 weeks of supplementation, the mice of group 1, the subgroup of Sucrose, further reduced their feed intake (p<0.001). In group 2, in the beginning, they consumed less amount of food in the Sucrose subgroup, although the Svetia® subgroup increased their food consumption. At the end of the treatment, the Splenda® subgroup consumed more food (p<0.001). When comparing group 1 with group 2, it can be seen that there are no differences (p<0.60) between the groups regarding the amount of consumption, the differences observed are between the subgroups.

3.5 Percentage of Lymphocytes of Peyer's Patches

In group 1, the percentage of lymphocytes increased in the Sucrose subgroup, but decreased in the Splenda® and Svetia® subgroups, although the differences are not significant (p<0.077). In group 2, a significant decrease can be seen in the subgroups that consumed sweeteners (p<0.028), particularly in the Sucrose subgroup (p<0.022), compared with the control subgroup. When comparing groups 1 and 2, differences in lymphocyte percentages can be appreciated, as well as the different behavior between strains.

Table 2. Blood glucose after 6 weeks of treatment with sweeteners

<table>
<thead>
<tr>
<th>Glucose</th>
<th>Control</th>
<th>Sucrose</th>
<th>Splenda®</th>
<th>Svetia®</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ±SD</td>
<td>Mean ±SD</td>
<td>Mean ±SD</td>
<td>Mean ±SD</td>
<td></td>
</tr>
<tr>
<td>Balb/c Group</td>
<td>110.7±14</td>
<td>100±16.3</td>
<td>96.8±10.8</td>
<td>108.5±9.5</td>
<td>0.122*</td>
</tr>
<tr>
<td>CD1 Group</td>
<td>174.1±33</td>
<td>201.6±43.8</td>
<td>133.2±40.7</td>
<td>205.7±47.3</td>
<td>0.001*</td>
</tr>
</tbody>
</table>

One-way ANOVA was performed to determine the differences between the subgroups, it was considered significant with p < .001. A Bonferroni post hoc test* was performed to observe intra-group differences

Table 3. Water consumption with and without sweetener for 6 weeks of treatment

<table>
<thead>
<tr>
<th>Water consumption with and without sweetener</th>
<th>Before intervention</th>
<th>After intervention (6 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>Sucrose</td>
</tr>
<tr>
<td></td>
<td>Mean ±SD (mL)</td>
<td>Mean ±SD (mg/mL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Balb/c Group</td>
<td>47.6±0.9</td>
</tr>
<tr>
<td></td>
<td>CD1 Group</td>
<td>61.6±0.4</td>
</tr>
<tr>
<td></td>
<td>43±1</td>
<td>166.3±1.1*</td>
</tr>
<tr>
<td></td>
<td>69±0.3</td>
<td>69±0.9</td>
</tr>
</tbody>
</table>

One-way ANOVA** was performed to determine the differences between the subgroups, it was considered significant with p < .001. A Bonferroni post hoc test* was performed to observe intra-group differences
Table 4. Consumption of food for 6 weeks of supplementation with sweetener

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Sucrose</th>
<th>Splenda®</th>
<th>Svetia®</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ±SD (g)</td>
<td>Mean ±SD (g)</td>
<td>Mean ±SD (g)</td>
<td>Mean ±SD (g)</td>
<td></td>
</tr>
<tr>
<td><strong>Before</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balb/c Group</td>
<td>32.08±0.02</td>
<td>24.08±0.011*</td>
<td>25.68±0.03*</td>
<td>29.92±0.034</td>
<td>0.001**</td>
</tr>
<tr>
<td>CD1 Group</td>
<td>27.1±0.32</td>
<td>25.6±0.641*</td>
<td>26.52±0.293</td>
<td>29.7±0.641*</td>
<td>0.001**</td>
</tr>
<tr>
<td><strong>After</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balb/c Group</td>
<td>32.9±0.755</td>
<td>16.07±0.939*</td>
<td>31.12±0.649</td>
<td>29.7±0.641</td>
<td>0.001**</td>
</tr>
<tr>
<td>CD1 Group</td>
<td>29.7±0.641</td>
<td>28±0.641</td>
<td>30±2.77*</td>
<td>27.7±0.320*</td>
<td>0.006**</td>
</tr>
</tbody>
</table>

One-way ANOVA** of one factor was performed to determine the differences between the subgroups, it was considered significant with p<0.05. A Bonferroni post hoc test* was performed to observe intra-group differences.

Table 5. Percentage of Peyer patches lymphocytes in mice supplemented with sweeteners for 6 weeks

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Sucrose</th>
<th>Splenda®</th>
<th>Svetia®</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ±SD %</td>
<td>Mean ±SD %</td>
<td>Mean ±SD %</td>
<td>Mean ±SD %</td>
<td></td>
</tr>
<tr>
<td><strong>Lymphocytes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balb/c Group</td>
<td>28.6±3.9</td>
<td>30±4.8</td>
<td>26.1±4.1</td>
<td>26.4±4.3</td>
<td>0.238</td>
</tr>
<tr>
<td>CD1 Group</td>
<td>74.3±4.3</td>
<td><strong>30.6±1.5</strong></td>
<td>43.8±2.2</td>
<td>49.1± 2.0</td>
<td>0.028**</td>
</tr>
</tbody>
</table>

ANOVA** of one factor was performed to determine the differences between the subgroups, it was considered significant with p<0.05. A Bonferroni post hoc test* was performed to observe intra-group differences.

4. DISCUSSION

4.1 Changes in Body Weight, Food and Water Consumption

The results presented in this study showed that mice of group 1 and 2 gained weight with Sucrose consumption, compared with the subgroups of Splenda® and Svetia®. In group 2, the Svetia® subgroup had lower weight gain compared to the Sucrose and Splenda® subgroups. Group 2 had greater weight gain; this may be due to the characteristics of the strain. Also, mice of group 1 had a greater predilection for the consumption of sweeteners, particularly of Sucrose, and lower for Splenda®. Group 2 had a greater predilection for the consumption of water with Svetia®. This behavior probably is derived from the absence or low energy content of Splenda® and Svetia® respectively [52,53], therefore, there was no increase in weight in these groups, compared with the group of Sucrose. It is a fact that drinks with high Sucrose content promote weight gain [54], and is associated with other metabolic disorders that cause states of inflammation and some types of cancer, such as colon cancer [55]. This effect may be because carbohydrates interact with receptors of the small intestine that cause secretion of satiety peptides such as the glucagon-like peptide 1 (GLP-1) [56], in addition to gastric distension caused by high water intake with sucrose.

The preference for water with sucrose in rodents is documented [57,58], and it has been linked to the discovery of sweet taste receptors T1R3 or gustducin in the intestine [59]. In contrast, in the study conducted by Bello and Hajnal in 2005 with rats, they showed that rats do not like drinks with Sucralose since the consumption of water without sucralose was similar to the consumption of water with Sucralose [60]. The preference of rodents to sweeteners like Stevia was also studied and it was observed that it has better acceptance compared to other non-caloric sweeteners such as saccharin [61]. This shows that there is variation in the preference between different non-caloric sweeteners and even between species such as mice and rats. Preference also varies between genera; females have a better response to sweetness than males [62].

In groups 1 and 2, Sucrose subgroups consumed less food, but in group 2, Splenda® and Svetia® increased food consumption. This situation can be attributed to the energy contribution of each sweetener, sucrose provides greater energy content, which causes a satiety sensation in
rodents and inhibits appetite. Groups of non-nutritive sweeteners, which contribute little or very few calories, could cause an increase in appetite [54].

4.2 Blood Glucose Changes

In group 2, sucralose showed a lower concentration compared to the other subgroups. In the Chang et al. study, in 2010, they evaluated the proximal small bowel exposure to sucralose, applied an intraduodenal glucose infusion in ten healthy subjects, took blood samples at frequent intervals and determined that Sucralose does not modify the glycemic response rate [63]. In addition to Sucralse, other artificial sweeteners report a glycemic index similar to Sucrose [64]. In another study conducted by Wang et al. in 2011, they investigated the effect of steviol on insulin resistance and the pro-inflammatory status of adipose tissue in mice fed a high-fat diet; oral administration had no effect on body weight, basal insulin levels, glucose tolerance, and insulin sensitivity improved and decreased secretion of inflammatory cytokines in adipose tissue [65], concluded that the use of Stevia is beneficial and helps control blood glucose levels.

A study designed to evaluate the effects of stevia on blood glucose concentration and blood pressure (BP) with the active treatment of steviol glucoside or placebo for 3 months. There were no changes in systolic/diastolic blood pressure, glucose concentration and glycosylated haemoglobin (HbA1c), therefore, oral stevia is well tolerated and has no pharmacological effect [19].

4.3 Changes in the Percentage of Lymphocyte from Peyer’s Patches

Studies on the effect of sweeteners on the immune system of the small intestine and particularly Peyer's patches are still scarce. In the study by Sehar et al. in 2008, they report that Stevia can stimulate the proliferation of T and B cells, increasing humoral and cellular immunity [40], in lymphocytes from the spleen, in Balb/c mice of both sexes, evaluated viability by stimulating lymphocytes in vitro directly with stevioside and did not decrease viability. This study was carried out on lymphocytes purified from Peyer's patches, as a site of the first contact with the ingested and absorption sweeteners. Also, the response between strains was different, in Balb/c mice (group 1) sucrose increased the percentage of lymphocytes from Peyer's patches, and in group CD1 (group 2), sucrose reduced this percentage. Another possible explanation for the decrease is found in the type of study and sweetener used. In in vitro studies where the product used not for commercial use (Esvetia/Truvia) if not reactive grade, stevia was administered at different doses, some superior to those used in this work, without differences in the results [66]. These results could be extrapolated to the human being since the metabolism of Stevia is similar between rodents and humans. On the other hand, the consumption of sucrose has been related to a decrease in the phagocytic index in neutrophils [36], which means that the consumption of sucrose can alter the function of the cells and particularly in the Peyer's patches as the first contact site of the sweetener. The effect of Sucralose on the immune response of inflammatory bowel diseases has been observed [67,68], in chronic inflammatory processes as a consequence of an increase in intestinal permeability [68] which causes immunological reactions against diet antigens and components of the intestinal microbiota [69]. In the study carried out by Abou-Donia et al. in rats indicated that Splenda has adverse effects such as reduced microbiota, increased faecal pH, and over-expression of proteins that limit the bioavailability of drugs [70]. The cause of the inhibition of the bacteria of the intestine is related to the deterioration of the digestive proteases caused by the consumption of Sucralrose [71] that increases the intestinal permeability that causes inflammation of the mucous membranes and that leads to the excessive activation of the lymphocytes, which contributes to the pathogenesis of the Intestinal Inflammatory Disease and the Crohn's disease [72,73].

5. CONCLUSION

The consumption of sweeteners may modify the proportion of lymphocytes from Peyer's patches and this variation depends significantly on the dose, frequency, and type of sweetener. Splenda® decreased significantly the proportion of lymphocytes in Peyer’s patches, particularly in the CD1 strain. As well, we found differences between strains in weight, preference of consumption of sweeteners and water with Splenda®, Svetia® and Sucrose when compared with the consumption of water free of sweetener.

ETHICAL APPROVAL

All authors hereby declare that "Principles of laboratory animal care" (NOM-062-ZOO-1999) were followed, as well as specific national laws
where applicable. All experiments have been examined and approved by the appropriate ethics committee.

**COMPETING INTERESTS**

Authors have declared that no competing interests exist.

**REFERENCES**


52. Rosales-Gómez CA, Martínez-Carrillo BE, Reséndiz-Albor AA, Ramírez-Durán N, Valdés-Ramos R, Mondragón-Velásquez T, et al. Chronic consumption of sweeteners and its effect on glycaemia, cytokines, hormones and lymphocytes of...
DOI: 10.1155/2018/1345282.
eCollection 2018.
DOI: 10.3945/jn.114.190652
DOI: doi.org/10.1017/S0029665110000947
DOI: 10.1155/2015/458470
Available:https://doi.org/10.9734/EJNFS/2017/36313
DOI: doi.org/10.9734/EJNFS/2017/36772
DOI: 10.1093/ajcn/85.3.651
DOI: 10.1093/ajcn/61.4.960S
DOI: 10.2174 / 1876823701002010116
DOI: 10.1073 / pnas.0706678104
DOI: 10.1016/j.nutres.2005.07.003


68. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474(7351):327-36. DOI: 10.1038/nature10213

69. Qin X. What made Canada become a country with the highest incidence of inflammatory bowel disease: Could sucralose be the culprit? Can J Gastroenterol. 2011;25(9):511.


© 2019 Guzmán-Cruz et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.